Unlike earlier GLP-1 receptor agonists, retatrutide is a triple agonist : GLP-1 receptor agonist suppresses appetite, slows gastric emptying, improves insulin sensitivity GIP receptor agonist enhances insulin release, amplifies GLP-1 effects Glucagon receptor agonist stimulates energy expenditure, fat metabolism, and potentially impacts lipid handling Clinical trials so far have shown remarkable weight loss (up to 24% in some studies) and strong metabolic improvements, including effects on lipids like LDL cholesterol
The balance between such effects, particularly over a prolonged timeframe, including effects at other GHSR1a monomers or GHSR1a heterodimers with other receptor types, must be taken into consideration
Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al
This slower gastric emptying leads to a more gradual increase in blood sugar levels, giving the body more time to respond and manage glucose effectively
Rita Kapoor help patients understand what to expect from semaglutide GLP-1 therapy and guides them through a personalized weight management plan